Many people’s symptoms worsen during the winter period. “We call this an exacerbation or a flare up, when you get ...
Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to ...
Human metapneumovirus (HMPV) can present with symptoms like the common cold, but there is a warning sign that you might have missed on your skin, according to a doctor ...
Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...
Tom Nolan reviews this week’s research Between 2000 and 2022 the National Institute for Health and Care Excellence (NICE) appraised 332 pharmaceuticals (with 83% getting positive recommendations). Had ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
News Medical on MSN4d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPDA study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...
Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback